Linked Life Data

20554167

Source:http://linkedlifedata.com/resource/pubmed/id/20554167

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2010-7-19
pubmed:abstractText
The recent availability of molecular targeted therapies leads to reconsideration of the treatment strategy in patients with distant metastases from differentiated thyroid carcinoma who are resistant to radioiodine therapy, and in patients with metastatic medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered, preferably in the context of a prospective trial.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1433-2981
pubmed:author
pubmed:copyrightInfo
Copyright (c) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
448-55
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Molecular targeted therapies for patients with refractory thyroid cancer.
pubmed:affiliation
Department of Nuclear Medicine and Endocrine Oncology, Centre de Référence Tumeurs Réfractaires de la Thyroïde, Institut Gustave Roussy and University Paris-Sud XI, Villejuif, France.
pubmed:publicationType
Journal Article, Review